GlassScriptPhysician profile
Nikhil B Patel
NPI 1023499076
$8,828.60
in general payments reported to CMS, 2019-2025
58 companies · $1,219 in 2025
The $1,219 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,432 · 2020: $466 · 2021: $1,749 · 2022: $1,312 · 2023: $1,562 · 2024: $1,089 · 2025: $1,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,446 · Long Term Medical Supply Or Device Loan: $382 · Education: $42.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,445.89 |
| Long Term Medical Supply Or Device Loan | $382.43 |
| Education | $42.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,474.64 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $1,057.06 | 2022-2025 | |
| Celgene Corporation | $586.04 | 2022-2025 | Pomalyst, Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $574.85 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Janssen Biotech, INC. | $496.66 | 2019-2025 | Darzalex, Rybrevant, Tecvayli |
| Amgen INC. | $369.14 | 2019-2023 | Nplate, Vectibix, Xgeva |
| Genentech USA, INC. | $356.29 | 2019-2025 | Tecentriq, Itovebi, Alecensa |
| Astellas Pharma US INC | $325.82 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $281.47 | 2021-2025 | |
| Incyte Corporation | $278.70 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $207.78 | 2020-2024 | Enhertu, Injectafer |
| Glaxosmithkline, LLC. | $198.30 | 2019-2025 | Ojjaara, Shingrix |
| Pfizer INC. | $197.07 | 2019-2025 | |
| Seagen INC. | $170.38 | 2019-2023 | Adcetris, Tukysa |
| Gilead Sciences, INC. | $160.50 | 2023-2025 | Trodelvy |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhil Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.